<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02682511</url>
  </required_header>
  <id_info>
    <org_study_id>CPI-IFE-004</org_study_id>
    <nct_id>NCT02682511</nct_id>
  </id_info>
  <brief_title>Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension</brief_title>
  <official_title>A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Ifetroban in Patients With Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension (SSc-PAH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cumberland Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cumberland Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this phase 2 multicenter, randomized, double-blind, placebo-controlled, study
      is to assess the safety and efficacy of ifetroban in patients with diffuse cutaneous systemic
      SSc (dcSSc) or SSc-associated pulmonary arterial hypertension (SSc-PAH).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, placebo-controlled, double-blind phase 2 trial of patients with
      dcSSc or SSc-PAH. Twenty participants with SSc-PAH and 14 participants with dcSSc will be
      randomized to receive either oral ifetroban daily or matching placebo. Study participants
      will be treated for 12 months, followed by a 30-day follow-up period. The study will test
      whether ifetroban is safe and statistically superior to placebo in reducing the effects of
      their disease at month 12 and explore the ability of ifetroban to prevent or reverse
      progression in patients with early disease duration and reverse established disease in
      patients with longer disease duration.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs) and Serious AEs (SAEs)</measure>
    <time_frame>56 weeks</time_frame>
    <description>Safety is measured using AEs, including clinical significant changes in vital signs, laboratory test abnormalities and clinical tolerability of ifetroban.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in forced vital capacity (FVC)</measure>
    <time_frame>Baseline, 12, 26, and 52 weeks</time_frame>
    <description>To determine if ifetroban improves pulmonary function in subjects with diffuse cutaneous SSc or SSc-PAH compared to placebo as measured by a change from baseline FVC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in diffusion capacity for carbon monoxide (DLCO)</measure>
    <time_frame>Baseline, 12, 26, and 52 weeks</time_frame>
    <description>To determine if ifetroban improves pulmonary function in subjects with diffuse cutaneous SSc or SSc-PAH compared to placebo as measured by a change from baseline diffusion capacity for carbon monoxide (DLCO)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the modified Rodnan skin score (mRSS)</measure>
    <time_frame>Baseline, 12, 26, 39, and 52 weeks</time_frame>
    <description>The efficacy of treatment on skin fibrosis will be measured by changes from baseline in mRSS, a measure of skin thickness, at 52 weeks.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline in ventricular function as determined by cardiac MRI</measure>
    <time_frame>Baseline, 26, and 52 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in ventricular function as determined by echocardiography</measure>
    <time_frame>Baseline, 26, and 52 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Improve skin and peripheral vascular disease as measured by active digital ulcer count</measure>
    <time_frame>Baseline, 12, 26, 39, and 52 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Improve skin and peripheral vascular disease as measured by the subject's self-assessment of pain in digits by a visual analog scale (VAS), if active digital ulcers are present.</measure>
    <time_frame>Baseline, 12, 26, 39, and 52 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in blood biomarkers</measure>
    <time_frame>Baseline, 26, and 52 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in skin biomarkers</measure>
    <time_frame>Baseline, 26, and 52 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in erythrocyte sedimentation rate</measure>
    <time_frame>Baseline, 26, and 52 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in subject-reported health status assessed by the Scleroderma Health Assessment Questionnaire (SHAQ)</measure>
    <time_frame>Baseline, 12, 26, 39, and 52 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in subject health and disability measurements as assessed by the World Health Organization Disability Assessment Assessment Schedule 2.0 (WHODAS 2.0)</measure>
    <time_frame>Baseline, 12, 26, 39, and 52 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in subject-reported gastro-intestinal tract symptoms as assessed by the University of California, Los Angles (UCLA) Scleroderma Clinical Trial Consortium (SCTC) Gastrointestinal Tract (GIT) Questionnaire</measure>
    <time_frame>Baseline, 12, 26, 39, and 52 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in subject-reported outcomes as assessed by the short-form health survey (SF-36)</measure>
    <time_frame>Baseline, 12, 26, 39, and 52 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Scleroderma, Diffuse</condition>
  <condition>Scleroderma, Systemic</condition>
  <condition>Scleroderma, Limited</condition>
  <condition>Sclerosis, Progressive Systemic</condition>
  <condition>Skin Diseases</condition>
  <condition>Connective Tissue Diseases</condition>
  <condition>Pathologic Processes</condition>
  <condition>Autoimmune Diseases</condition>
  <arm_group>
    <arm_group_label>Patients with dcSSc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with dcSSc will be randomized to receive either oral ifetroban or oral placebo daily for 365 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with SSc-PAH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with SSc-PAH will be randomized to receive either oral ifetroban or oral placebo daily for 365 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Ifetroban</intervention_name>
    <description>Subjects will be treated with oral ifetroban or placebo daily for 365 days</description>
    <arm_group_label>Patients with SSc-PAH</arm_group_label>
    <arm_group_label>Patients with dcSSc</arm_group_label>
    <other_name>Ifetroban</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Placebo</intervention_name>
    <description>Subjects will be treated with oral ifetroban or placebo daily for 365 days</description>
    <arm_group_label>Patients with SSc-PAH</arm_group_label>
    <arm_group_label>Patients with dcSSc</arm_group_label>
    <other_name>Ifetroban</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Diffuse Cutaneous Criterion:

        1. Systematic Sclerosis (SSc), as defined using the 2013 American College of Rheumatology/
        European Union League Against Rheumatism Classification Criteria and dcSSc within 7 years
        following initial diagnosis as defined by the onset of the first non-Raynaud symptom.

        SSc-PAH Criteria:

          1. Adults fulfilling the 2013 American College of Rheumatology/ European Union League
             Against Rheumatism Classification Criteria with confirmed SSc-PAH (limited or dcSSc)
             confirmed via previous cardiac catheterization

          2. Stable oral therapy for PAH for at least 30 days (monotherapy or combination)

          3. New York Heart Association (NYHA) Class I-III Heart Failure

        Exclusion Criteria:

          1. Have a diagnosis of systemic sclerosis sine scleroderma;

          2. Be less than 18 years of age or greater than or equal to 80 years of age;

          3. Be pregnant, nursing, or planning to become pregnant;

          4. Current or planned treatment with prostanoid therapy;

          5. Current or planned treatment with pirfenidone;

          6. Use of rituximab in the last 3 months;

          7. Use of mycophenolic acid (Myfortic, CellCept) at a stable dose for less than 3 months;

          8. Current or planned corticosteroid therapy greater than 15mg per day of prednisone or
             prednisone equivalent;

          9. Significant lung disease, defined as FVC &lt; 50% predicted or DLCO &lt;40% predicted;

         10. Significant kidney disease, defined as Glomerular Filtration Rate (GFR) &lt; 60 ml/min;

         11. Have moderate or severe hepatic impairment;

         12. Contraindication to MRI (e.g., implanted magnetic material, claustrophobia);

         13. Known hypersensitivity to gadolinium;

         14. Any cause of pulmonary hypertension other than World Health Organization (WHO) Group I
             associated with SSc;

         15. Use of aspirin &gt; 81 mg per day in the last two weeks;

         16. Use of warfarin, heparin or other anticoagulants in the last 30 days;

         17. Recent (within 6 weeks) myocardial infarction or persistent atrial arrhythmias;

         18. Have a history of allergy or hypersensitivity to ifetroban;

         19. Have taken investigational drugs within 30 days before study treatment administration;

         20. Inability to understand the requirements of the study, inability to understand spoken
             English and abide by the study restrictions and to return for the required treatments
             and assessments;

         21. Be otherwise unsuitable for the study, in the opinion of the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evan Brittain, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Byron Kaelin, RN, BSHS</last_name>
    <phone>615-255-0068</phone>
    <phone_ext>250</phone_ext>
    <email>bkaelin@cumberlandpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jerry Fox, DVM</last_name>
    <phone>615-255-0068</phone>
    <phone_ext>226</phone_ext>
    <email>jfox@cumberlandpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1670</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nashla Barroso</last_name>
      <phone>310-825-9682</phone>
    </contact>
    <investigator>
      <last_name>Suzanne Kafaja, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Life Medical Research Center, Inc.</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Diaz, BS</last_name>
      <phone>786-360-3750</phone>
      <email>diaz@newlifemedresearch.com</email>
    </contact>
    <investigator>
      <last_name>Odalys P Frontela, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gwen Leatherman, RN, MS, CCRP</last_name>
      <phone>410-550-8582</phone>
    </contact>
    <investigator>
      <last_name>Laura Hummer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Frenandez</last_name>
      <phone>617-724-2792</phone>
    </contact>
    <investigator>
      <last_name>Flavia Castelino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston University School of Medicine</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Stratton, MTS, MPH</last_name>
      <phone>617-358-6777</phone>
      <email>eas@bu.edu</email>
    </contact>
    <investigator>
      <last_name>Marcin Trojanowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beemnet Amdemicael</last_name>
      <phone>212-774-2123</phone>
    </contact>
    <investigator>
      <last_name>Jessica Gordon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathan Wilson</last_name>
      <phone>843-792-8272</phone>
    </contact>
    <investigator>
      <last_name>Richard Silver, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Baylor Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75204-651</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Susan</last_name>
    </contact>
    <investigator>
      <last_name>Susan Mathai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christine Chan, BA, CCRC</last_name>
      <phone>206-342-6976</phone>
      <email>Christine.chan@virginiamason.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Carlin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KDH - Kokilaben Dhirubhai Ambani Hospital</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400053</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gauri Pandit, MBBS</last_name>
      <email>Gauri.Pandit@relianceada.com</email>
    </contact>
    <contact_backup>
      <last_name>Sanchita Gupte, MBBS</last_name>
      <email>sanchita.gupte@relianceada.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sunil Singh, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>B. J. Government Medical College</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vijaya Chavan</last_name>
      <email>orion.vijayachavan@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Arohi Metkar</last_name>
      <email>Orion.arohi@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>India</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>February 8, 2016</study_first_submitted>
  <study_first_submitted_qc>February 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2016</study_first_posted>
  <last_update_submitted>August 13, 2019</last_update_submitted>
  <last_update_submitted_qc>August 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ifetroban</keyword>
  <keyword>Scleroderma</keyword>
  <keyword>Systemic Sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Scleroderma, Localized</mesh_term>
    <mesh_term>Skin Diseases</mesh_term>
    <mesh_term>Connective Tissue Diseases</mesh_term>
    <mesh_term>Scleroderma, Limited</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Pathologic Processes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ifetroban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

